Literature DB >> 2061926

2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase.

C H Baker1, J Banzon, J M Bollinger, J Stubbe, V Samano, M J Robins, B Lippert, E Jarvi, R Resvick.   

Abstract

It has been found that 2'-deoxy-2'-methyleneuridine (MdUrd), 2'-deoxy-2'-methylenecytidine (MdCyd), and 2'-deoxy-2',2'-difluorocytidine (dFdCyd) 5'-diphosphates (MdUDP (1) MdCDP (2) and dFdCDP (3), respectively) function as irreversible inactivators of the Escherichia coli ribonucleoside diphosphate reductase (RDPR). 2 is a much more potent inhibitor than its uridine analogue 1. It is proposed that 2 undergoes abstraction of H3' to give an allylic radical that captures a hydrogen atom and decomposes to an active alkylating furanone species. RDPR also accepts 3 as an alternative substrate analogue and presumably executes an initial abstraction of H3' to initiate formation of a suicide species. Both 2 and 3 give inactivation results that differ from those of previously studied inhibitors. The potent anticancer activities of MdCyd and dFdCyd indicate a significant chemotherapeutic potential. The analogous RDPR of mammalian cells should be regarded as a likely target and/or activating enzyme for these novel mechanism-based inactivators.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2061926     DOI: 10.1021/jm00110a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

1.  Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.

Authors:  Md Faiz Ahmad; Intekhab Alam; Sarah E Huff; John Pink; Sheryl A Flanagan; Donna Shewach; Tessianna A Misko; Nancy L Oleinick; William E Harte; Rajesh Viswanathan; Michael E Harris; Chris Godfrey Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

2.  Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases.

Authors:  Jun Wang; Gregory J S Lohman; JoAnne Stubbe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

3.  5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.

Authors:  Jonathan M Rawson; Richard H Heineman; Lauren B Beach; Jessica L Martin; Erica K Schnettler; Michael J Dapp; Steven E Patterson; Louis M Mansky
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

4.  Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.

Authors:  Taro Okazaki; Milind Javle; Motofumi Tanaka; James L Abbruzzese; Donghui Li
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

5.  Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.

Authors:  Michael M Im; Sheryl A Flanagan; Jeffrey J Ackroyd; Donna S Shewach
Journal:  Radiat Res       Date:  2015-01-07       Impact factor: 2.841

6.  Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.

Authors:  Sarah E Huff; Faiz Ahmad Mohammed; Mu Yang; Prashansa Agrawal; John Pink; Michael E Harris; Chris G Dealwis; Rajesh Viswanathan
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

7.  Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.

Authors:  Xiaoqun Dong; Li Jiao; Yanan Li; Douglas B Evans; Huamin Wang; Kenneth R Hess; James L Abbruzzese; Donghui Li
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

8.  Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification.

Authors:  Gregory J S Lohman; Joanne Stubbe
Journal:  Biochemistry       Date:  2010-02-23       Impact factor: 3.162

9.  Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation.

Authors:  Andrea Schäfer; Lars Schomacher; Guillermo Barreto; Gabi Döderlein; Christof Niehrs
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

10.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.